Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-0e387e560fa6e1178c04c02876196a66",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-0e387e560fa6e1178c04c02876196a66",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-0e387e560fa6e1178c04c02876196a66",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-0e387e560fa6e1178c04c02876196a66\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-0e387e560fa6e1178c04c02876196a66</b></p><a name=\"composition-en-0e387e560fa6e1178c04c02876196a66\"> </a><a name=\"hccomposition-en-0e387e560fa6e1178c04c02876196a66\"> </a><a name=\"composition-en-0e387e560fa6e1178c04c02876196a66-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1419/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - trepulmix</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/19/1419/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp0e387e560fa6e1178c04c02876196a66"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - trepulmix",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Trepulmix is and what it is used for</li><li>What you need to know before you use Trepulmix</li><li>How to use Trepulmix</li><li>Possible side effects</li><li>How to store Trepulmix</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What trepulmix is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What trepulmix is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Trepulmix is The active ingredient of Trepulmix is treprostinil. Treprostinil belongs to a group of medicines which work in a similar way to the naturally occurring prostacyclins. Prostacyclins are hormone-like substances which reduce blood pressure by relaxing blood vessels, causing them to widen, which allows the blood to flow more easily. Prostacyclins can also have an influence in preventing blood from clotting.</p><p>What Trepulmix is used to treat Trepulmix is used for the treatment of adult patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment (severity classified WHO Functional Class (FC) III or IV), to improve exercise capacity and symptoms of the disease. Chronic thromboembolic pulmonary hypertension is a condition where your blood pressure is too high in the blood vessels between the heart and the lungs causing shortness of breath, dizziness, tiredness, fainting, palpitations or abnormal heartbeat, dry cough, chest pain and swollen ankles or legs.</p><p>How Trepulmix works Trepulmix lowers blood pressure within the pulmonary artery by improving blood flow and reducing the amount of work for the heart. Improved blood flow leads to an increased supply of oxygen to the body and reduced strain on the heart, causing it to function more effectively. Trepulmix improves the symptoms associated with CTEPH and the ability to exercise in patients who are limited in terms of activity.</p></div>"
}
},
{
"title" : "2. What you need to know before you take trepulmix",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take trepulmix"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use Trepulmix:</p><ul><li>if you are allergic to treprostinil or any of the other ingredients of this medicine (listed in section 6).</li><li>if you have been diagnosed with a disease called pulmonary veno-occlusive disease . This is a disease in which the blood vessels that carry blood through your lungs become swollen and clogged resulting in a higher pressure in the blood vessels between the heart and the lungs.</li><li>if you have severe liver disease</li><li>if you have a heart problem, for example: a heart attack (myocardial infarction) within the last six months severe changes in heart rate severe coronary heart disease or unstable angina a heart defect has been diagnosed, such as a faulty heart valve that causes the heart to work poorly any disease of the heart which is not being treated or not under close medical observation</li><li>if you are at a specific high risk of bleeding for example active stomach ulcers, injuries or other bleeding conditions</li><li>if you have had a stroke within the last 3 months, or any other interruption of blood supply to the brain</li></ul><p>Warnings and precautions Talk to your doctor before using Trepulmix if you:</p><ul><li>suffer from any liver disease</li><li>suffer from kidney disease</li><li>have been advised that you are medically obese (BMI greater than 30 kg/m2)</li><li>are on a low sodium diet</li></ul><p>During your treatment with Trepulmix, tell your doctor:</p><ul><li>if your blood pressure decreases (hypotension)</li><li>if you experience a rapid increase in breathing difficulties or persistent cough (this can be related to congestion in the lungs or asthma or other condition), consult your doctor immediately.</li><li>if you have excessive bleeding as treprostinil may increase the risk, by preventing your blood from clotting</li></ul><p>Children and adolescents Trepulmix must not be used in children and adolescents.</p><p>Other medicines and Trepulmix Tell your doctor if you are taking/using, have recently taken/used or might take/use any other medicines. Please tell your doctor if you are taking:</p><ul><li>medicines used to treat high blood pressure (antihypertensive medicines or other vasodilators)</li><li>medicines used to increase the rate of urination (diuretics) including furosemide</li><li>medicines that stop blood clotting (anticoagulants) such as warfarin, heparin or nitric oxide based products</li><li>any non-steroidal anti-inflammatory (NSAID) medicines (e.g. acetylsalicylic acid, ibuprofen)</li><li>medicines which may enhance or weaken the effects of Trepulmix (e.g. gemfibrozil, rifampicin, trimethoprim, deferasirox, phenytoin, carbamazepine, phenobarbital, St. John's wort.), as your doctor may need to adjust the dosage of Trepulmix.</li></ul><p>Pregnancy and breast-feeding Trepulmix is not recommended if you are pregnant, planning to become pregnant, or think that you might be pregnant, unless considered essential by your doctor. The safety of this medicine for use during pregnancy has not been established.</p><p>Contraception is strongly recommended during Trepulmix treatment.</p><p>Trepulmix is not recommended for use in breast-feeding, unless considered essential by your doctor. You are advised to stop breast-feeding if Trepulmix is prescribed for you, because it is not known whether this medicine passes into breast milk.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Driving and using machines Trepulmix may induce low blood pressure with dizziness or fainting. In such a case do not drive or operate machinery and ask your doctor for advice.</p><p>Trepulmix contains sodium Please tell your doctor if you are on a controlled sodium diet. They will take into account: Trepulmix 1 mg/ml solution for infusion This medicine contains 36.8 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 1.8% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>Trepulmix 2.5 mg/ml solution for infusion This medicine contains 37.3 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 1.9% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>Trepulmix 5 mg/ml solution for infusion This medicine contains 39.1 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 2.0% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>Trepulmix 10 mg/ml solution for infusion This medicine contains 37.4 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 1.9% of the recommended maximum daily dietary intake of sodium for an adult.</p></div>"
}
},
{
"title" : "3. How to take trepulmix",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take trepulmix"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>Trepulmix is administered undiluted as a continuous subcutaneous infusion (under the skin) via a small tube (cannula) which is located in your abdomen or thigh;</p><p>Trepulmix is pushed through the tubing by a portable pump.</p><p>Before you leave the hospital or clinic, your doctor will tell you how to prepare Trepulmix and at<br/>what rate the pump should deliver your treprostinil. Information on how to use the pump correctly and what to do if it stops working should also be given to you. The information should also tell you who to contact in an emergency. Flushing of the infusion line whilst connected may cause accidental overdose.</p><p>Adult patients Trepulmix is available as 1 mg/ml, 2.5 mg/ml, 5 mg/ml or 10 mg/ml solution for infusion. Your doctor will determine the infusion rate and dose appropriate for your condition.</p><p>Elderly patients No special dose adjustments are necessary for these patients.</p><p>Patients with liver or kidney disease Your doctor will determine the infusion rate and dose appropriate for your condition.</p><p>Infusion rate The infusion rate can be reduced or increased on an individual basis under medical supervision only.</p><p>The aim of adjusting the infusion rate is to establish an effective maintenance rate which improves symptoms of CTEPH while minimising any undesirable effects.</p><p>If your symptoms increase or if you need complete rest, or are confined to your bed or chair, or if any physical activity brings on discomfort and your symptoms occur at rest, do not increase your dose without medical advice. Trepulmix may no longer be sufficient to treat your disease and another treatment may be required.</p><p>If you use more Trepulmix than you should If you accidentally overdose Trepulmix, you may experience nausea, vomiting, diarrhoea, low blood pressure (dizziness, light-headedness or fainting), skin flushes and/or headaches.</p><p>If any of these effects become severe you should contact your doctor or hospital immediately. Your doctor may reduce or discontinue the infusion until your symptoms have disappeared. Trepulmix solution for infusion will then be reintroduced at a dose level recommended by your doctor.</p><p>If you stop using Trepulmix Always use Trepulmix as directed by your doctor or hospital specialist. Do not stop using Trepulmix unless your doctor has advised you to.</p><p>Abrupt withdrawal or sudden reductions in the dose of Trepulmix may cause the pulmonary arterial hypertension to return with the potential for rapid and severe deterioration in your condition.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>widening of blood vessels</li><li>pain around the infusion site</li><li>reaction around the infusion site</li><li>bleeding or bruising around the infusion site</li><li>headaches</li><li>nausea</li><li>diarrhoea</li><li>jaw pain</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>dizziness</li><li>light-headedness or fainting due to low blood pressure</li><li>skin rashes</li><li>muscle pain (myalgia)</li><li>joint pain (arthralgia)</li><li>swelling of feet, ankles, legs or fluid retention</li><li>hot flush</li><li>pain in arms and / or legs Uncommon (may affect up to 1 in 100 people)</li><li>swollen eyelids (eyelid oedema)</li><li>indigestions</li><li>vomiting</li><li>skin itches</li><li>exanthema</li><li>back pain</li><li>decreased appetite</li><li>tiredness</li></ul><p>Other possible side effects observed in pulmonary arterial hypertension (PAH) patients:</p><ul><li>bleeding episodes such as: as nose bleeds, coughing up blood, blood in the urine, bleeding from the gums, blood in the faeces</li></ul><p>Other possible side effects observed during clinical practice:</p><ul><li>infection at the infusion site</li><li>abscess at the infusion site</li><li>a decrease of blood clotting cells (platelets) in the blood (thrombocytopenia)</li><li>bone pain</li><li>skin rashes with discolouration or raised bumps</li><li>tissue infection under the skin (cellulitis)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.* By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store trepulmix",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store trepulmix"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date that is stated on the carton and vial after EXP . The expiry date refers to the last day of that month.</p><p>This medicinal product does not require any special storage conditions.</p><p>A Trepulmix vial must be used or discarded within 30 days after first opening.</p><p>During continuous subcutaneous infusion, a single reservoir (syringe) of undiluted Trepulmix must be used within 72 hours.</p><p>Do not use this medicine if you notice any damage to the vial, discolouration or other signs of deterioration.</p><p>Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Trepulmix contains The active substance is treprostinil.</p><p>Trepulmix 1 mg/ml solution for infusion Each ml of solution contains 1 mg treprostinil (as sodium salt). Each 10 ml vial of solution contains 10 mg treprostinil (as sodium salt).</p><p>Trepulmix 2.5 mg/ml solution for infusion Each ml of solution contains 2.5 mg treprostinil (as sodium salt) Each 10 ml vial of solution contains 25 mg treprostinil (as sodium salt).</p><p>Trepulmix 5 mg/ml solution for infusion Each ml of solution contains 5 mg treprostinil (as sodium salt). Each 10 ml vial of solution contains 50 mg treprostinil (as sodium salt).</p><p>Trepulmix 10 mg/ml solution for infusion Each ml of solution contains 10 mg treprostinil (as sodium salt). Each 10 ml vial of solution contains 100 mg treprostinil (as sodium salt).</p><p>The other ingredients are: Sodium citrate, sodium chloride, sodium hydroxide, hydrochloric acid, metacresol and water for injections. See section 2, Trepulmix contains sodium .</p><p>What Trepulmix looks like and the contents of the pack Trepulmix is a clear colourless to slightly yellow solution, available in a 10 ml clear glass vial sealed with a rubber stopper and a colour coded cap:</p><p>Trepulmix 1 mg/ml solution for infusion Trepulmix 1 mg/ml solution for infusion has a yellow rubber cap.</p><p>Trepulmix 2.5 mg/ml solution for infusion Trepulmix 2.5 mg/ml solution for infusion has a blue rubber cap.</p><p>Trepulmix 5 mg/ml solution for infusion Trepulmix 5 mg/ml solution for infusion has a green rubber cap.</p><p>Trepulmix 10 mg/ml solution for infusion Trepulmix 10 mg/ml solution for infusion has a red rubber cap.</p><p>Each carton contains one vial.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation holder SciPharm S rl 7, Fausermillen L-6689 Mertert Luxembourg</p><p>Manufacturer AOP Orphan Pharmaceuticals GmbH Leopold-Ungar-Platz 2 1190 Vienna Austria</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien<br/>AOP Orphan Pharmaceuticals GmbH (Austria) T l/Tel: +43 1 5037Lietuva<br/>AOP Orphan Pharmaceuticals GmbH (Austrija) Tel: + 43 1 5037<br/>AOP Orphan Pharmaceuticals GmbH ( ) Te .: + 43 1 5037Luxembourg/Luxemburg<br/>AOP Orphan Pharmaceuticals GmbH (Austria)<br/>T l/Tel: + 43 1 5037 esk republika<br/>AOP Orphan Pharmaceuticals GmbH (Rakousko) Tel: + 43 1 5037Magyarorsz g<br/>AOP Orphan Pharmaceuticals GmbH (Ausztria) Tel.: + 43 1 5037Danmark<br/>AOP Orphan Pharmaceuticals GmbH ( strig) Tlf: + 43 1 5037Malta<br/>AOP Orphan Pharmaceuticals GmbH (L-Awstrija) Tel: + 43 1 5037Deutschland<br/>AOP Orphan Pharmaceuticals Germany GmbH Tel: + 49 89 99 740 7Nederland<br/>AOP Orphan Pharmaceuticals GmbH (Oostenrijk) Tel: + 43 1 5037Eesti<br/>AOP Orphan Pharmaceuticals GmbH (Austria) Tel: + 43 1 5037Norge<br/>AOP Orphan Pharmaceuticals GmbH ( sterrike) Tlf: + 43 1 5037<br/>AOP Orphan Pharmaceuticals GmbH ( ) : + 43 1 5037 sterreich<br/>AOP Orphan Pharmaceuticals GmbH Tel: + 43 1 5037Espa a<br/>AOP Orphan Pharmaceuticals Iberia S.L.<br/>Tel: +34 91 395 40 Polska<br/>AOP Orphan Pharmaceuticals GmbH (Austria) Tel.: + 43 1 5037France<br/>AOP Orphan Pharmaceuticals GmbH (Autriche) T l: + 43 1 5037Portugal<br/>AOP Orphan Pharmaceuticals GmbH (Austria) Tel: + 43 1 5037Hrvatska<br/>AOP Orphan Pharmaceuticals GmbH (Austrija) Tel: + 43 1 5037Rom nia<br/>AOP Orphan Pharmaceuticals GmbH (Austria) Tel: + 43 1 5037Ireland<br/>AOP Orphan Pharmaceuticals GmbH (Austria) Tel: + 43 1 5037Slovenija<br/>AOP Orphan Pharmaceuticals GmbH (Avstrija) Tel: + 43 1 5037 sland<br/>AOP Orphan Pharmaceuticals GmbH (Austurr ki) S mi: + 43 1 5037Slovensk republika<br/>AOP Orphan Pharmaceuticals GmbH (Rak sko) Tel: + 43 1 5037Italia<br/>AOP Orphan Pharmaceuticals GmbH (Austria) Tel: + 43 1 5037Suomi/Finland<br/>AOP Orphan Pharmaceuticals GmbH (It valta) Puh/Tel: + 43 1 5037<br/>AOP Orphan Pharmaceuticals GmbH ( ) : + 43 1 5037Sverige<br/>AOP Orphan Pharmaceuticals GmbH ( sterrike) Tel: + 43 1 5037Latvija<br/>AOP Orphan Pharmaceuticals GmbH (Austrija) Tel: + 43 1 5037United Kingdom (Northern Ireland)<br/>AOP Orphan Pharmaceuticals GmbH (Austria) Tel: + 43 1 5037This leaflet was last revised in .</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp0e387e560fa6e1178c04c02876196a66",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp0e387e560fa6e1178c04c02876196a66",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp0e387e560fa6e1178c04c02876196a66\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp0e387e560fa6e1178c04c02876196a66</b></p><a name=\"mp0e387e560fa6e1178c04c02876196a66\"> </a><a name=\"hcmp0e387e560fa6e1178c04c02876196a66\"> </a><a name=\"mp0e387e560fa6e1178c04c02876196a66-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1419/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Trepulmix 1 mg/ml solution for infusion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/19/1419/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Trepulmix 1 mg/ml solution for infusion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
